Neuren Pharmaceuticals Limited (OTCMKTS:NURPF – Get Free Report) was the target of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totaling 16,560 shares, a decrease of 89.2% from the July 15th total of 152,860 shares. Based on an average daily volume of 2 shares, the short-interest ratio is currently 8,280.0 days.
Neuren Pharmaceuticals Stock Performance
Neuren Pharmaceuticals stock opened at C$17.00 on Friday. Neuren Pharmaceuticals has a 1 year low of C$7.70 and a 1 year high of C$17.25. The firm’s 50 day moving average price is C$12.15 and its two-hundred day moving average price is C$10.16.
Neuren Pharmaceuticals Company Profile
Neuren Pharmaceuticals (OTCMKTS:NURPF) is an Australian-based clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for the treatment of neurodevelopmental and neurodegenerative disorders. The company’s research efforts center on addressing unmet medical needs in conditions such as Rett syndrome, Fragile X syndrome and Angelman syndrome. Neuren is publicly traded on the Australian Securities Exchange and maintains an over-the-counter listing in the United States, reflecting its commitment to global capital markets and investor engagement.
The company’s lead candidate, trofinetide (NNZ-2566), is a synthetic analogue of a naturally occurring peptide that has been evaluated in late-stage clinical trials for Rett syndrome and Fragile X syndrome.
Featured Stories
- Five stocks we like better than Neuren Pharmaceuticals
- Why Are Analysts Freaking Out About Apple’s All-Glass iPhone?
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
